Chase Sun Pharma Named Among "Top 100 Chinese Pharmaceutical Companies"

On September 7, the 41st National Pharmaceutical Industry Information Conference, hosted by the China Pharmaceutical Industry Information Center and supported by the China Pharmaceutical Industry Research Institute, took place in Chengdu. During the event, Chase Sun Pharmaceuticals was once again recognized as one of the "Top 100 Chinese Pharmaceutical Companies" for 2023, highlighting its strength in pharmaceutical innovation and advanced manufacturing.

Over the years, Chase Sun Pharmaceuticals has embraced an innovation-driven development strategy, establishing a comprehensive health industry matrix that spans multiple sectors. The company has built a high-tech pharmaceutical health industry group that integrates investment, production, R&D, and sales.

Since 2021, Chase Sun Pharmaceuticals has launched the "Digital Chase Sun" strategy, driving digital transformation in production, quality control, and sales. By implementing advanced digital systems, the company has optimized processes, improved quality control, and enhanced marketing precision. In 2024, Chase Sun further deepened its collaboration with Huawei Cloud, leveraging AI to optimize production and material demand planning, reduce inventory, and improve overall operational efficiency, gaining a competitive edge in the market.